Pharmesis International (SGX:BFK) Debt-to-Equity : 0.32 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International Debt-to-Equity?

Pharmesis International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was S$2.88 Mil. Pharmesis International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was S$0.20 Mil. Pharmesis International's Total Stockholders Equity for the quarter that ended in Dec. 2023 was S$9.53 Mil. Pharmesis International's debt to equity for the quarter that ended in Dec. 2023 was 0.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharmesis International's Debt-to-Equity or its related term are showing as below:

SGX:BFK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.21 Max: 0.32
Current: 0.32

During the past 13 years, the highest Debt-to-Equity Ratio of Pharmesis International was 0.32. The lowest was 0.06. And the median was 0.21.

SGX:BFK's Debt-to-Equity is ranked worse than
51.53% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs SGX:BFK: 0.32

Pharmesis International Debt-to-Equity Historical Data

The historical data trend for Pharmesis International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International Debt-to-Equity Chart

Pharmesis International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.26

0.28

0.30

0.31

0.32

Pharmesis International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.30	0.31	0.31	0.30	0.32

Competitive Comparison of Pharmesis International's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmesis International's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharmesis International's Debt-to-Equity falls into.

Pharmesis International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharmesis International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.882	+	0.201)	/	9.528
	=	0.32

Pharmesis International's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.882	+	0.201)	/	9.528
	=	0.32

Pharmesis International (SGX:BFK) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pharmesis International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharmesis International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmesis International (SGX:BFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Kallang Sector, No. 03-02, Singapore, SGP, 349279

Website

https://www.pharmesis.com

Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its geographical segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International (SGX:BFK) Headlines

From GuruFocus

Certain BlackRock Municipal Closed-End Funds Announce Variable Rate Muni Term Preferred Shares Actions

By Business Wire • 11-02-2023